地诺帕明|Denopamine|cas:71771-90-9|西域试剂

地诺帕明,Denopamine,99%

产品编号：Bellancom-119515| CAS NO：71771-90-9| 分子式：C₁₈H₂₃NO₄| 分子量：317.38

地诺帕明((R)-(-)-地诺帕明)是一种口服活性、选择性β1-肾上腺素能激动剂。地诺帕明延长病毒性心肌炎所致充血性心力衰竭小鼠模型的存活时间：抑制心脏肿瘤坏死因子-α的产生。心血管效应。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-119515	￥1700.00	杭州北京（现货）
Bellancom-119515	￥3800.00	杭州北京（现货）
Bellancom-119515	￥6200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

地诺帕明

产品介绍

Denopamine ((R)-(-)-Denopamine) 是一种有效的，具有口服活性的的选择性 β1-肾上腺素能 (β1-adrenergic) 激动剂。Denopamine 可延长病毒性心肌炎诱发的充血性心力衰竭小鼠模型的存活时间：抑制心脏中肿瘤坏死因子-α 的产生。具有心血管效应。

生物活性

Denopamine ((R)-(-)-Denopamine) is an orally active, selective β1-adrenergic agonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Cardiovascular effects.

体外研究

Denopamine (0.1-100 μM) suppresses LPS-induced TNF-α production in a concentration-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Murine spleen cells
Concentration:	0, 0.1, 1, 10, 100 μM
Incubation Time:	5 hours
Result:	Decreased TNF-α levels by 96.9±6.7%, 62.7±6.5%, 53.2±8.8%, and 40.3±1.5% at 0.1, 1, 10 and 100 μmol/L, respectively.

体内研究
(In Vivo)

Denopamine (14 μmol/kg per day; oral administration; for 14 days) significantly improves the survival of the animals, attenuates myocardial lesions, and suppresses TNF-α production in vivo.
The plasma concentration of Denopamine is 13.1±1.9 nmol/L at 1 h, 4.3±0.9 nmol/L at 2 h, 1.8±0.5 nmol/L at 3 h, and <0.6 nmol/L at 5 h after its administration. A single 14 μmol/kg dose of denopamine in mice produces a peak level at 1 h.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-week-old inbred male DBA/2 mice
Dosage:	14 μmol/kg per day
Administration:	Oral administration; 14 days
Result:	Treatment significantly improved the survival of the animals (14 of 25 (56%) treated, vs 5 of 25 (20%) control mice). At day 14, the survival rate of 57.1% (16 of 28 mice) in the treated group was significantly higher than the 33.3% (10 of 30 mice) survival rate in the control group. The survival rate from day 6 to day 14 was also significantly improved in the treated group (69.6%; 16 of 23 mice) versus the control group (45.5%; 10 of 22 mice, p < 0.05).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-week-old inbred male DBA/2 mice
Dosage:	14 μmol/kg per day
Administration:	Oral administration; 14 days
Result:	Treatment significantly improved the survival of the animals (14 of 25 (56%) treated, vs 5 of 25 (20%) control mice). At day 14, the survival rate of 57.1% (16 of 28 mice) in the treated group was significantly higher than the 33.3% (10 of 30 mice) survival rate in the control group. The survival rate from day 6 to day 14 was also significantly improved in the treated group (69.6%; 16 of 23 mice) versus the control group (45.5%; 10 of 22 mice, p < 0.05).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four-week-old inbred male DBA/2 mice
Dosage:	14 μmol/kg per day
Administration:	Oral administration; 14 days
Result:	Treatment significantly improved the survival of the animals (14 of 25 (56%) treated, vs 5 of 25 (20%) control mice). At day 14, the survival rate of 57.1% (16 of 28 mice) in the treated group was significantly higher than the 33.3% (10 of 30 mice) survival rate in the control group. The survival rate from day 6 to day 14 was also significantly improved in the treated group (69.6%; 16 of 23 mice) versus the control group (45.5%; 10 of 22 mice, p < 0.05).

性状

Solid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (15.75 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1508 mL	15.7540 mL	31.5080 mL
5 mM	0.6302 mL	3.1508 mL	6.3016 mL
10 mM	0.3151 mL	1.5754 mL	3.1508 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. R Nishio, et al. Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. J Am Coll Cardiol. 1998 Sep;32(3):80 [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS08
信号词	Warning
危害声明	H361
警示性声明	P281
个人防护装备	Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
危害码 (欧洲)	Xn: Harmful;
风险声明 (欧洲)	R62
安全声明 (欧洲)	S22;S45;S36/S37/S39
危险品运输编码	NONH for all modes of transport
RTECS号	DA4795470

1. 物质的识别

产品名：	Denopamine
CAS号：	71771-90-9
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Denopamine
别名：	(R)-(-)-Denopamine; TA-064
分子式：	C18H23NO4
分子量：	317.38

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。